Inducing T cells to treat and prevent disease - Corporate Presentation - Solebury Trout Access
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Inducing T cells to treat and prevent disease Corporate Presentation V2_JUL NON-CONFIDENTIAL
Company Overview
Platform
• Proprietary ChAdOx (prime) and MVA (boost) technology platform licensed from University of Oxford; induces and
maintains high levels of CD8+ T cells against target antigens
Therapeutic Pipeline
• Ph1/2 HPV and HBV immunotherapy data H2 2021 – first HBV participant dosed June 23
• Ph2 Prostate cancer, 5T4 immunotherapeutic data recently released
• Ph1/2 NSCLC MAGE-NYESO immunotherapeutic enters clinic in Q2 2021
External funding - 4 of 6 projects in co-development
• Leading Ph3 ChAdOx COVID-19 vaccine out-licensed to Oxford Uni/AstraZeneca with post-pandemic revenue stream
• Leading ChAdOx MERS coronavirus vaccine, Ph1 immunogenicity and safety data, increasing partner interest
• Platform positions Vaccitech to rapidly develop vaccines for future pandemic threats
Our Our
3 Founders Investors
Strong scientific, clinical and financial foundations
• $150M funding
• Over 15 years of human studies
• 5,000 participants vaccinated
Established 2016
ChAdOx-MVA platform*
• Over 160 vaccine technologies •
• Many assessed head-to-head for CD8+ T cell induction • $60M raised
• ChAd-MVA consistently superior • $8.6M non-dilutive funding
• Over 3,000 participants in trials
• MVA, ChAd, • 35 employees
DNA, • >4000 sq. ft of lab space
fowlpox,
protein, • Significant external validation
adjuvants, with partners
VLPs
Ewer et al (2017)
Hum Vaccin
Immunother.
*Exclusive rights to the platform in multiple infectious
disease and all oncology indications
• In multiple indications:
4 Ebola, Malaria, Hepatitis C, TB, HIV, Influenza
Vaccitech Pipeline
Product Program IND-enabling Phase 1 Phase 2 Phase 3 Vaccitech Rights
Prostate cancer therapeutic
VTP-800 Worldwide
with checkpoint inhibitor
VTP-300 HBV therapeutic Worldwide
VTP-200 HPV therapeutic Worldwide
NSCLC therapeutic with
VTP-600 Worldwide (76% of JV)
checkpoint inhibitor
Worldwide
VTP-400 Zoster prophylactic (excl. China)
MERS Coronavirus
VTP-500 Worldwide
prophylactic
VTP-900/ COVID-19 Coronavirus
Licensed to OU-AZ
AZD1222 prophylactic
5
Vaccitech Technology Platform
ChAdOx-MVA
6
Immunity against infection and cancer is indication-specific
ChAdOx (Prime) MVA (Boost)
5’ DNA 3’ 5’ DNA 3’
Gene(s) Cell
replicated and Transgene Transgene
transcribed
Cytotoxic T
lymphocyte
Cell-mediated and B cell boost
CD8+ subset has been difficult to induce
Antigen with competitive technologies
presenting
Viral/tumor
cells
antigenic Targets foreign elements to protect against
peptide and clear viruses and cancers
Humoral and cellular immune
response prime
CD4+ and CD8+ T cells Optimal immune
Prophylactic and therapeutic
efficacy against viral infection responses to treat and
(e.g., COVID-19, MERS, Zoster) prevent disease
7
Antibodies
ChAd-MVA provides powerful antigen-specific T cell induction
Leading CD8+ T cell-inducing platform in man
Platform safely mimics potent natural viral infections, using heterologous prime-boost
Prime Boost Key Platform Features:
• Vectors encode the same transgene
Chimpanzee Adenovirus Avian-adapted
1 – 12 weeks • Only boost target antigen responses
Oxford 1 and 2 (ChAdOx) Modified Vaccinia
• No anti-vector immunity (unlike most
Ankara (MVA)
human adenoviruses)
Indicative Human T cell response, antigen, invariant chain1
HCVFeatures:
Key Platform Optimal immunogenicity
• Vectors encode the same
• Quantity: greater CD8+ T cell stimulation than other platforms
transgene
MVA• Only boost target antigen • Quality: T cells polyfunctional
boost responses
• No anti-vector immunity (unlike • Duration: Sustained T cell levels
ChAd most human adenoviruses)
prime
Excellent safety
• Neither vector can replicate in man
Convenient administration
• Intramuscular injection of each vector given 1 week to 3
months apart
8
1 Esposito et al (2020) Science Translational Medicine, Vol. 12, Issue 548 – Median T cell response in 10 healthy participants
CD4+ & CD8+ T generates
ChAd-MVA cell Induction in magnitude
high Humans (Infectious
CD8+ TDiseases)
cell responses in humans
In Infectious Disease vs. foreign viral antigens In Oncology and even vs. self-antigens
Induction of balanced CD8+ and CD4+ T cells – ex vivo ELISPOT Average ex vivo T cell (with CD8+) induction in responding patients
ChAdOx-MVA.5T4
ChAd-MVA
Phase 1 Phase 3 Pre-registration Phase 1
(Flu) (HPV) (Ebola) (HCV)
Licenced Terminated Phase 2 Phase 1
(mCRPC) Phase 3 (Melanoma) (Prostate
(mCRPC) cancer)
RNA: Bahl 2017, Mol Ther. 25:1316-1327, DNA: Trimble 2015, Lancet 386:2078-2088, Other viral vectors: Harari 2012, Eur J Immunol 42:3038-48; Dahlke 2017,
EBioMedicine 19: 107–118. ChAd-MVA: Ewer et al. 2016, NEJM; Ogwang et al 2015, Sci Transl Med. 7:286re5.
9 Provenge Nadeem A. Sheikh at al. 2012 Cancer Immunol Immunotherapy, Vaccinia/Fowlpox Gulley et al (2013) Cancer Immunol. research, 2(2), pp.133-141.
RNA Sahin U. et al. Nature 2017 ChAd-MVA: Redchenko et al 2018 Journal of Clinical Oncology 36, 3018-3018.
©
ChAdOx-MVA platform is differentiated and well-positioned
The heterologous prime-boost approach is at the cutting edge
• Large pharma and biotechs (including GSK, J&J, Pfizer, Gritstone) also utilizing
this approach to induce CD8+ T cells
• Targeting disease settings where CD8+ T cells are needed, including chronic viral
infections and cancer
Proprietary, innovative product design
• Proprietary promoters increasing immunogenicity
• Innovative encoded molecular adjuvants
• Novel, global antigen insert designs
Highly scalable and reliable production
• Proprietary manufacturing cell lines for speed, scale and efficiency
• Eight GMP clinical lots already produced and processes confirmed for
commercial scale
10 • Cost of goods lower than most powerful T cell-based technologies
ChAdOx (Prime) – MVA (Boost)
Therapeutic Pipeline
Leveraging the Vaccitech Platform across multiple targets in
infectious disease and cancer
11VTP-300
VTP-300: Phase 1 ongoing for a functional HBV cure
Need Approach and Data Plan
C57BL6 mice vaccinated with
5x10^7 IU of ChAdOx1-HBV-v2 and 2x10^6 PFU of MVA-HBV-v2(low GC)
Spleenocyte repsonse T cells Abs
12000
11000
Goal: Functional cure
10000
9000
8000
7000
6000
(sustained loss of HepB sAg)
5000
4000
>30% of treated patients
IFN-γ SFU/106
Spleenocytes
3000
2000
1000
500
400
300 • Phase 1 underway in CHB
200
• >250M people 100 patients
0
chronically infected SI
i
F2
A
nk
er
1 &2
Co
re
Po
l-1
Po
l -2
Po
l-3
Po
l-4
Pr
eS
1/
S2
Su
rfa
c e
To
t al
• Select the appropriate dose(s)
Li
with HBV Non-HBV HBV peptides
for development at Phase 2
vaccine HBV peptides
components
• >70M infected with with anti-PD1
Genotype C Broad preclinical HBV-specific T cell and Ab responses1
• Expand HBV populations
• There is no cure for • Encodes all of surface antigen, inactivate polymerase, core Phase 2/3
CHB • Explore different anti-PD(L)1
• In combination with low-dose Checkpoint Inhibitor and
• Global HBV market: antivirals for Phase 3 and various
over $2B antiviral targets
• Consensus sequence using Genotype C
12
1 Chinnakannan et al (2020) Vaccines 2020, 8, 184VTP-300
HBV001 and HBV002 – High level study designs
HBV001 Healthy Participants CHB Participants
Phase 1
(UK, initiated)
Cohort 1 (N=5) LD Cohort 2 (N=5) HD
Cohort 3 (N=6) LD Cohort 4 (N=6) HD
ChAdOx1-HBV ChAdOx1-HBV
FPFV (HP): dosed June 2.5 x 109 vp 2.5 x 1010 vp
ChAdOx1-HBV ChAdOx1-HBV
FPFV (CHB): Q320 2.5 x 109 vp 2.5 x 1010 vp
Fully enrolled Fully enrolled
Group 1 (N=16)
• HBV DNAVTP-200
VTP-200: Phase 1 ready therapeutic for high-risk HPV
Need Approach and Data Plan
Eliminate persistent high-
risk HPV infection and HPV-
associated early cervical
lesions
• 10M cases of high-risk • Phase 1/2 (105 CIN1/2 HPV
HPV infection in US patients) start Q3 2020,
and EU each year efficacy read-out Q4 2021
• No therapeutic drug • Conduct Phase 2b/3 adaptive
for persistent infection VTP-200 elicits higher magnitudes of CD8+ T cells trial(s) suitable for licensure.
• Induction of CD8+ T than DNA1 • Expand the indications to
cells partially effective Targets all high-risk genotypes using 6 early proteins: include Anal Intraepithelial
• Breakthrough Neoplasia (AIN), vulvar
• E1, E2, E4, E5, E6, E7
therapeutic peak sales neoplasia, and other
• From HPV16, 18, 31, 52, 58 potential HPV pre-cancerous
approximately $1.4B
(US and 5EU) • Includes 59 conserved amino acid regions lesions (oral)
14
1 Hancock et al (2019) Scientific Reports, 9(1), pp.1-12.VTP-200
VTP-200: HPV001, Phase 1/2a – Q3 2020
Trial Timelines Main phase (N=96) Patients high-risk HPV positive for >6 months
Countries
FPFV Q3 20 Placebo controlled, blinded, randomised: Safety, efficacy,
Belgium dose-response
LPFV Q1 21
UK
LPLV Q4 22 Group 1 (N=16)
ChAdOx1-HPV 2 x 109 vp; MVA-HPV 1 x 107 pfu
Lead-in (N=9) Efficacy: % clearance of
Patients high-risk HPV positive for >6 months: Group 2 (N=16) high-risk HPV and % of
immunogenicity ChAdOx1-HPV 2 x 1010 vp; MVA-HPV 1 x 107 pfu
cervical lesions
evaluated at 12 months
Group 3 (N=8)
ChAdOx1-HPV 2 x 108 vp; MVA-HPV 1 x 108 pfu
Group C (N=3)
Data anticipated:
ChAdOx1-HPV 2 x 1010 vp 6 month HPV clearance
Group 4 (N=8)
MVA-HPV 1 x 107 pfu ChAdOx1-HPV 2 x 109 vp; MVA-HPV 1 x 108 pfu data – Q4 2021
Group 5 (N=16) Expansion: 12 month
Group B (N=3)
ChAdOx1-HPV 2 x 109 vp ChAdOx1-HPV 2 x 1010 vp; MVA-HPV 1 x 108 pfu data analysis, or interim
MVA-HPV 1 x 107 pfu if efficacy signal
Group 6 (N=32)
Placebo
Group A (N=3)
ChAdOx1-HPV 2 x 108 vp
MVA-HPV 1 x 107 pfu
15VTP-800
VTP-800: In Phase 2 with anti-PD-1 for prostate cancer
Prostate cancer is the most common & 2nd leading cause of cancer death in men
Phase 1: VANCE Phase 2a: ADVANCE
Immunogenicity complete: ChAdOx1 + MVA prime
boost (34 early-stage prostate cancer patients) Study in metastatic patients using
ChAdOx-MVA plus a checkpoint inhibitor
• High CD8+ T cell responses to the human self-
antigen 5T4, an oncofetal protein
• 23 mCRPC patients recruited
• CD8+ T cells also • Efficacy readouts: reduction in PSA levels,
infiltrated tumor
ctDNA
• Presented at • Primary endpoint: >50% reduction in PSA
ASCO 2018 compared to baseline
• Published BMJ1 • Comparator anti-PD-1 alone response ~9%2
• PFS, OS (Secondary endpoints)
Ex vivo overnight T cell responses (n.b., not in vitro stimulated) to
5T4 peptide pools (IFNγ ELISPOT) , 64% of patients responded
Investigator-led trials sponsored by University of Oxford and funded by EU grant
16
1 Cappuccini, F. et al. Journal for ImmunoTherapy of Cancer 2020, 2 Antonarakis, E. et al. Journal of Clinical Oncology 2020VTP-800
ADVANCE: KEYNOTE-199 comparison
In collaboration with Prof Adrian Hill, Dr Irina Redchenko and Dr Mark Tuthill, University of Oxford
Data ADVANCE (N=23) KEYNOTE-1991 Stats*
(N=243)
Patients Progressing mCRPC Progressing mCRPC
Opdivo 480 mg on weeks
Pembro 200 mg q3 for
4, 8, 12
Regimen up to
(VTP-800 prime-boost on
35 weeks
weeks 0, 4, 12, 16)
115, 116, 43 ng/mL in
Median PSA at start 88 ng/mL
3 cohorts
Responses of > 50% P = 0.059* * Fisher’s
22% (5/23) 9% (21/243) exact test
at any timepoint P = 0.10**
** with
Responses with Yates
P = 0.057*
confirmation at 3 17.4% (4/23) 5.8% (14/243) correction
P = 0.09**
weeks later
Full clinical analysis pending, initial safety data is
comparable to that seen from dosing anti-PD-1 alone
17 1 Antonarakis, E. et al. Journal of Clinical Oncology 2020VTP-600
VTP-600: Novel MAGE-A3 and NY-ESO-1 therapeutic
In collaboration with Prof Benoit Van Den Eynde, Ludwig Cancer Research
• MAGE-A3 and NY-ESO-1: immunogenic tumor-associated
Background
antigens, highly specific to cancer cells
• NSCLC, gastro-esophageal, melanoma and bladder express
both antigens
1 Normalised Lung Skin
according to
Esophageal
squamous cell cutaneous Mean tumour growth - 15V4T3
carcinoma
RPKM Bladder carcinoma Melanoma
Head and Neck 800
Urothelial DPY control
Mean tumor volume (mm3)
Carcinoma squamous cell
carcinoma Chemo only
600
aPD-1 only
• Improves efficacy of anti-PD-1 and Vaccine only
****
Approach and data
400
****
chemotherapy Vaccine + chemo
200 Vaccine + aPD-1
• Design allows patient selection based Chemo + aPD-1
on NY-ESO and/or MAGE expression 0
Vaccine + aPD-1 + chemo
0 10 20 30 40 50
• First-in-human Proof-of-Concept trial Days post tumour implantation
Q2 2021, sponsored by CRUK DBA/2 mice, P1A tumors, mastocytoma cell line
One round of prime-boost – ChAdOx day 8, MVA day 151
18
1 Data on fileIn collaboration with
VTP-600
VTP-600: High-level Phase 1/2a clinical design
SoC therapy phase and recruitment (STAGE 1)
Patient is diagnosed Phase 1/2a trial (STAGE 2)
and commences 2 cycles of SoC chemo and anti-PD-1
standard of care (SoC) (6 wks at 200mg/dose)
treatment Day 1 Day 28
(C3) PFS, OS, ORR
Data anticipated: Q1 2023
NSCLC VTP-600 arm + SoC
40 patients
During the 2 cycles of SoC:
Randomization
(Non-blinded)
• Screening procedures Boost - MVA- SoC given which can continue while
(MAGE-A3 and NY-ESO- Patient Prime - MAGE-A3 alone
patient is receiving benefit
1 expression) ChAdOx- or
• Biopsy MAGE-A3-NY- MVA-MAGE-A3
ESO-1 and MVA-NY- VTP-600 re-boosting as indicated from
• Consent to the trial
ESO-1 patient response
NSCLC SoC arm
40 patients
GOJ VTP-600 + SoC + anti-PD-1
15 patient biomarker arm
19Series B/Crossover
Overview & Use of Proceeds
20Financial overview
Money raised to date: Series B Funding / Use of Proceeds:
• $13M (£10M) Seed March 2016 $55M to fund through Q1 2022
• $32M (£26M) Series A 2018 • Phase 2a efficacy readout in HBV
• New investors in each A round • Phase 2a efficacy readout in HPV
• $3M Ludwig investment into joint venture 2018 • Prostate cancer Phase 2b readout
• BARDA funding $8.6M Jan 2019 • General corporate purposes
Post money (Series A):
• $86M
Through Partners/External Funding:
Cash into Q2 2021: • COVID-19 vaccine license revenue
• $4.2M June 2020 • MERS Phase 1 data
• Zoster Phase 1 data
• $3.5M R&D tax credits due prior to Aug 2020
• NSCLC – Phase 1/2b start
• AZ upfront milestone receipt in Jul
• $12.3M convertible note closed Jul
21Series B – Use of Proceeds through Q1 2022 ($55M)
Anticipated spend:
• HPV to end Phase 1/2a (H2-2021) $25M
• HBV to end Phase 1/2a (H2-2021) $25M
• Prostate Phase 2b $12M
• G&A $8M
• Research / Development $4M
• Rapid Adeno Manufacturing (RAM) $2M
• VOLT / MAGE (Phase 1/2a funded externally) $3M
• Flu Wind down $1M
Less:
• Cash at May 2020 ($3M)
• Future Fund matched investment ($13M)
• Astra Zeneca/OU licence upfront ($2M)
• UK Parent R&D Tax credit ($5M)
• Australian subsidiary R&D Tax credit ($2M)
Net spend $55M
22Accomplishments & Upcoming Milestones
Key value drivers and upcoming catalysts
Completed Upcoming Series B
Milestones Milestones Milestones
Early partnerships and collaborations • Prostate Cancer (VTP-800) Phase 2a • ChAdOx COVID-19 vaccine available
(MERS, Flu, Zoster, NSCLC) interim readout Q1 2020 for pandemic use in Q3 2020*
HPV, HBV and NSCLC therapeutics in • OU COVID-19 Phase 1 start Q2 2020 • ChAdOx COVID-19 non-emergency
GMP manufacture use regulatory approval milestones
• Revenue upon finalization of OU-AZ in 2021**
Appointment of Bill Enright as Chief license**
Executive Officer • HBV (VTP-300) efficacy readout
• HBV (VTP-300) Phase 1 enrollment (sAg loss) H2 2021
MERS coronavirus (VTP-500) Phase 1 completed by Q3
readout • HPV (VTP-200) efficacy readout
• HBV (VTP-300) Phase 2a start Q3 2020 (lesion and % HPV viral clearance)
Successful execution of Phase 2b H2 2021
studies for Universal Influenza A • HPV (VTP-200) Phase 1 start Q3 2020
vaccine (VTP-100) • MERS coronavirus (VTP-500) Saudi • NSCLC (VTP-600) Phase 1/2a first-
Arabia Phase 1 data Q3 2020** line start Q2 2021
23
*Best case timing based on clinical success and manufacturing scale up forecasts ** Milestones generated through external fundingProphylactic products
Externally funded programs and pandemic readiness
24Pipeline of prophylactic products
Platform technology continues to be validated through partners and non-dilutive funding
IND-
Product Program Phase 1 Phase 2 Phase 3 Vaccitech Rights Funding
enabling
VTP-900/ COVID-19 Coronavirus
Licensed to OU-AZ
AZD1222 prophylactic
Funded by
Worldwide
VTP-400 Zoster prophylactic (excl. China)
CanSino through
Phase 1
CEPI invested
MERS Coronavirus
VTP-500 Worldwide $19M to develop
prophylactic MERS program
25Expertise and a platform to accelerate pandemic preparedness
GMP material
Vaccine design Non-GMP Animal studies
for FIH trial
Virus sequence optimised Research stock generated
for animal studies, stability
tested
2 weeks 3 weeks 3-12 weeks
GMP 12 weeks
• ChAdOx shows efficacy in animal models of Lassa/Nipah; Phase 1 studies in Zika and Chikungunya
• Rapid design and transfer of ChAdOx COVID-19 vaccine for human trials now shown; million dose scale up ongoing
• Proprietary simian-adenovirus vectors (ChAdOx and undisclosed) for future vaccine projects
26VTP-500
ChAdOx1 MERS Coronavirus Phase 1: Durable humoral and cellular immune responses
Antibodies: Individual IgG titres at different dose groups T cells: Ex vivo IFN-γ ELISpot T cell responses to Spike
• Single dose of ChAdOx1 induced strong Ab and T cell responses that persisted when measured 1 year post vaccination
• ChAdOx1 MERS induces a strong and sustained cellular immune response at all doses tested
• A strong Th1 response is associated with protection from immunopathology in animal models
• Human data and vaccine design informed ChAdOx COVID-19 vaccine development
27
Gilbert et al (2020) Lancet IDChAdOx1 nCoV-19 Phase 1/2: Robust anti-viral immune responses in people with COVID-19
Antibodies: neutralising Ab titers in participants T cells: Ex vivo IFN-γ ELISpot T cell responses
and convalescent plasma samples to SARS-CoV-2 Spike
• Neutralising Ab responses similar to range seen in convalescent COVID-19 patients
• Antigen-specific T cell responses detected in all participants without artificial culturing
• No SAEs reported, safety comparable to other ChAdOx trials
• Differentiated induction of both humoral and cellular immune responses against SARS-CoV-2
28
Folegatti et al (2020) Lancet IDCOVID-19 Overview
MHRA Pts #
Ph 1 UK High level study design
1,112
Conditional Licensure –
Clinical Development
Ph 2/3 UK Q3 2020 10,000 • Initial safety and immunogenicity
Adaptive
design
Ph 2/3 South Africa
• Phase 2/3 randomized efficacy studies
in adults and children with
Ph 2/3 US 30,000 comparator vaccine
Ph 2/3 Brazil 5,000
Efficacy data EMA Registration
referenced for EU requirements
licensure
Govt, public
29 funding £65M $1.2B $750MVaccitech & Oxford University COVID-19 Partnership with AZ
VTP-900 / AZD-1222 • Vaccitech held platform rights and jointly invented COVID-19 vaccine with OU
Vaccine History & IP • Vaccitech led ex-UK (mostly US and EU) early development until license to OU/AZ
• Grant of global development, manufacturing and distribution license
OU / AZ Deal Summary • Vaccitech and OU are foregoing royalties on pandemic period sales (est. July ’21)
• May 2020 license structure includes upfront, milestones & royalties
• Vaccitech receives 24% of revenue paid under OU/AZ agreement
Management Revenue • Vaccitech not responsible for any development/commercial expenses
• Milestones: estimated >$10 million of license revenues to Vaccitech through
Estimates
approvals (2020-22), plus several million more upon achievement of sales
thresholds in first 12-18 months
Clear multi-billion-dollar
• Vaccitech revenue eNPV is ~$300 million (management model, prob adjusted)
market opportunity in the
very near term • Potential peak royalties to Vaccitech of ~$140 million per year (post-pandemic)
30Platform company with short-term commercial milestones
• Proprietary ChAdOx (prime) and MVA (boost) platform creates powerful therapeutic and prophylactic products
• Clinical-stage therapeutic pipeline, near-term efficacy readouts in major infectious disease and oncology indications
• Externally funded pipeline includes leading COVID-19 vaccine
• Ph1/2 immunogenicity data positive, Ph3 trial ongoing and on track for efficacy data Q3
• Ongoing Series B / Crossover funds efficacy readouts in HBV, HPV, Prostate Cancer therapeutics
• Positive ChAdOx COVID-19 vaccine efficacy data (expected Q3) would position Vaccitech for a Q4 US IPO
Our Our
31 Founders InvestorsAppendix 32
Board of Directors & Advisors 39
Vaccitech Board & Scientific Advisors
Prof Adrian Hill
Prof Sarah Gilbert
Co-Founder and Scientific Advisor
Co-Founder, Board Director and Scientific Advisor
Director of the Jenner Institute at University of Oxford
Professor of Vaccinology at University of Oxford
Patricia Fast, MD, Ph.D.
Robin Wright
Scientific Advisor – Infectious Disease
Chairman
International AIDS Vaccine Initiative
Extensive experience as Chief Financial Officer of public
companies in Pharma and Biotech
Jerome Kim
Scientific Advisor – Infectious Disease
Alex Hammacher Director General of the International Vaccine Institute
Non-executive Director
Stephen Dewhurst
Lead life sciences investor for Oxford Sciences Innovation
Scientific Advisor – Infectious Disease
Chair of Microbiology and Immunology at the University of Rochester
Pierre A Morgon
Non-executive Director Bruce Innis
Over 30 years experience in global vaccine and immunotherapy companies Scientific Advisor – Infectious Disease
Leader, Respiratory Infections and Maternal Immunizations,
PATH Center for Vaccine Innovation and Access
In addition, Bill Enright, Board Director (CEO) and
Tom Evans, Board Director (CSO)
40Oncology Scientific Advisors
Justin Stebbing Charles G. Drake
Scientific Advisor - Oncology Scientific Advisor - Oncology
Professor of Cancer Medicine and Co-Director, Cancer
Oncology at Imperial College London Immunotherapy Programs at
Columbia, Herbert Irving
Benoit Van den Eynde Drew Pardoll
Scientific Advisor - Oncology Scientific Advisor - Oncology
Professor of Tumor Immunology, Professor of Oncology, Johns
Ludwig Institute for Cancer Research Hopkins University, School of
Medicine
Mark Middleton Mark Tuthill
Scientific Advisor - Oncology Scientific Advisor - Oncology
Head of Department of Oncology. Consultant oncologist at the Churchill
Early Phase Clinical Trials & Hospital, OUH NHS FT
Melanoma Therapy
41Intellectual Property 42
Intellectual property
Platform technology protected by global patent portfolio
Vector/Platform
Patent portfolio • ChAdOX1 patent (PCT/GB2012/000467 expiring 2032) granted and pending
• ChAdOx2 patent (PCT/GB2017/051851 expiring 2037) granted (GB) and pending
• Patent applications covering
platform technologies and • Rapid Adeno Method (PCT/EP2019/073181 expiring 2039) pending
specific products are owned by
Products
Oxford University Innovation
• MERS patent (PCT/GB2018/051399 expiring 2038) pending
• Vaccitech is exclusive licensee to
platform for use in specific • HBV patent (PCT/GB2018/050948 expiring 2038) pending
infectious diseases
• MVA-F11.5T4 patent (PCT/EP2019/062694 expiring 2039) pending
• Vaccitech is exclusive licensee to
ChAdOx platform for all • HPV patent (PCT/GB2018/052335 expiring 2038) pending
therapeutic cancer vaccine uses • VZV patent priority application (GB1818084.4 expiring 2038) pending
• Vaccitech is also non-exclusive
licensee to platform for use in Promoters for increased immunogenicity
most other Infectious Disease • Adenoviral promoter patent (PCT/GB2008/001262 expiring 2028) granted in EP and US
indications
• MVA F11 promoter patent (PCT/GB2011/050757 expiring 2031) granted in EP and US
• Shark invariant chain patent (EP3077408 and US15/101,282 expiring 2034) pending
43You can also read
